A Case Report of Anticoagulation Management in Acquired Hemophilia Associated With Levofloxacin.

PURPOSE

To report a case of acquired hemophilia secondary to levofloxacin and provide a guide for the use of anticoagulation in acute coronary syndrome.

CASE SUMMARY

A 75-year-old female treated with levofloxacin presented with spontaneous bruising of the upper extremities. Levofloxacin was discontinued and the symptoms resolved. Thereafter, the spontaneous bruising recurred and progressed over a few weeks. The patient was treated with recombinant factor VIIA with a time to recuperation of 3 months. The patient was subsequently found to have ST-segment elevation for which they received unfractionated heparin, ticagrelor, and aspirin prior to bare metal stent placement.

CONCLUSION

Hemophilia A is a rare disease associated with high morbidity and mortality. Case studies previously evaluating the association of levofloxacin with acquired hemophilia have shown causality. Initiating anticoagulation in patients with acquired hemophilia has long been a challenge to clinicians as evidence-based guidelines are lacking and bleeding risk may outweigh the benefit of anticoagulation. Furthermore, factor VIII deficiency does not provide additive protection against atherosclerotic plaque formation. This case report supports existing literature associating levofloxacin with acquired hemophilia. Due to the complication of life-threatening bleeds, familiarity with the treatment course following coronary events will allow patients with acquired hemophilia to be adequately and safely anticoagulated.